230 related articles for article (PubMed ID: 24287492)
1. Glioblastoma multiforme therapy and mechanisms of resistance.
Ramirez YP; Weatherbee JL; Wheelhouse RT; Ross AH
Pharmaceuticals (Basel); 2013 Nov; 6(12):1475-506. PubMed ID: 24287492
[TBL] [Abstract][Full Text] [Related]
2. Breaching barriers in glioblastoma. Part I: Molecular pathways and novel treatment approaches.
Miranda A; Blanco-Prieto M; Sousa J; Pais A; Vitorino C
Int J Pharm; 2017 Oct; 531(1):372-388. PubMed ID: 28755993
[TBL] [Abstract][Full Text] [Related]
3. Glutathione S-Transferase M3 Is Associated with Glycolysis in Intrinsic Temozolomide-Resistant Glioblastoma Multiforme Cells.
Cheng SY; Chen NF; Wen ZH; Yao ZK; Tsui KH; Kuo HM; Chen WF
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34209254
[TBL] [Abstract][Full Text] [Related]
4. Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme.
Gainer JL; Sheehan JP; Larner JM; Jones DR
J Neurosurg; 2017 Feb; 126(2):460-466. PubMed ID: 27177177
[TBL] [Abstract][Full Text] [Related]
5. Emerging Cellular Therapies for Glioblastoma Multiforme.
Choi PJ; Tubbs RS; Oskouian RJ
Cureus; 2018 Mar; 10(3):e2305. PubMed ID: 29755901
[TBL] [Abstract][Full Text] [Related]
6. Disentangling the therapeutic tactics in GBM: From bench to bedside and beyond.
Daisy Precilla S; Kuduvalli SS; Thirugnanasambandhar Sivasubramanian A
Cell Biol Int; 2021 Jan; 45(1):18-53. PubMed ID: 33049091
[TBL] [Abstract][Full Text] [Related]
7. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.
Niranjan A; Kano H; Iyer A; Kondziolka D; Flickinger JC; Lunsford LD
J Neurosurg; 2015 Apr; 122(4):757-65. PubMed ID: 25594327
[TBL] [Abstract][Full Text] [Related]
8. Leveraging metabolomics to assess the next generation of temozolomide-based therapeutic approaches for glioblastomas.
St-Coeur PD; Touaibia M; Cuperlovic-Culf M; Morin P
Genomics Proteomics Bioinformatics; 2013 Aug; 11(4):199-206. PubMed ID: 23732626
[TBL] [Abstract][Full Text] [Related]
9. Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients.
Agnihotri S; Gajadhar AS; Ternamian C; Gorlia T; Diefes KL; Mischel PS; Kelly J; McGown G; Thorncroft M; Carlson BL; Sarkaria JN; Margison GP; Aldape K; Hawkins C; Hegi M; Guha A
J Clin Invest; 2012 Jan; 122(1):253-66. PubMed ID: 22156195
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic therapies in glioblastoma multiforme.
McNamara MG; Mason WP
Expert Rev Anticancer Ther; 2012 May; 12(5):643-54. PubMed ID: 22594899
[TBL] [Abstract][Full Text] [Related]
11. The Ig superfamily protein PTGFRN coordinates survival signaling in glioblastoma multiforme.
Aguila B; Morris AB; Spina R; Bar E; Schraner J; Vinkler R; Sohn JW; Welford SM
Cancer Lett; 2019 Oct; 462():33-42. PubMed ID: 31377205
[TBL] [Abstract][Full Text] [Related]
12. Aldehyde dehydrogenase 1A1--a new mediator of resistance to temozolomide in glioblastoma.
Schäfer A; Teufel J; Ringel F; Bettstetter M; Hoepner I; Rasper M; Gempt J; Koeritzer J; Schmidt-Graf F; Meyer B; Beier CP; Schlegel J
Neuro Oncol; 2012 Dec; 14(12):1452-64. PubMed ID: 23132408
[TBL] [Abstract][Full Text] [Related]
13. The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells.
Johannessen TC; Prestegarden L; Grudic A; Hegi ME; Tysnes BB; Bjerkvig R
Neuro Oncol; 2013 Mar; 15(3):269-78. PubMed ID: 23258843
[TBL] [Abstract][Full Text] [Related]
14. Autophagy inhibition potentiates SAHA‑mediated apoptosis in glioblastoma cells by accumulation of damaged mitochondria.
Lohitesh K; Saini H; Srivastava A; Mukherjee S; Roy A; Chowdhury R
Oncol Rep; 2018 Jun; 39(6):2787-2796. PubMed ID: 29658588
[TBL] [Abstract][Full Text] [Related]
15. Glioblastoma multiforme: Diagnosis, treatment, and invasion.
Li J; Feng L; Lu Y
J Biomed Res; 2022 Oct; 37(1):47-58. PubMed ID: 36403983
[TBL] [Abstract][Full Text] [Related]
16. MicroRNAs as Multifaceted Players in Glioblastoma Multiforme.
Mercatelli N; Galardi S; Ciafrè SA
Int Rev Cell Mol Biol; 2017; 333():269-323. PubMed ID: 28729027
[TBL] [Abstract][Full Text] [Related]
17. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
[TBL] [Abstract][Full Text] [Related]
18. Nanotechnology for Treatment of Glioblastoma Multiforme.
Michael JS; Lee BS; Zhang M; Yu JS
J Transl Int Med; 2018 Sep; 6(3):128-133. PubMed ID: 30425948
[TBL] [Abstract][Full Text] [Related]
19. Synergistic drug combinations for a precision medicine approach to interstitial glioblastoma therapy.
Graham-Gurysh EG; Murthy AB; Moore KM; Hingtgen SD; Bachelder EM; Ainslie KM
J Control Release; 2020 Jul; 323():282-292. PubMed ID: 32335153
[TBL] [Abstract][Full Text] [Related]
20. The Role of Kinase Signaling in Resistance to Bevacizumab Therapy for Glioblastoma Multiforme.
Ramezani S; Vousooghi N; Joghataei MT; Chabok SY
Cancer Biother Radiopharm; 2019 Aug; 34(6):345-354. PubMed ID: 31411929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
